A phase I dose escalation study of Nimotuzumab
This presentation is the property of its rightful owner.
Sponsored Links
1 / 4

Zhao Kuai-le 1 , Hu Xi-chun 2 , Wu Xiang-hua 2 , Fu Xiao-long 1 , Fan Min 1 , Jiang Guo-liang 1 PowerPoint PPT Presentation


  • 115 Views
  • Uploaded on
  • Presentation posted in: General

A phase I dose escalation study of Nimotuzumab in combination with concurrent chemoradiation for patients with locally advanced squamous cell carcinoma of esophagus. (presentation number 1026). Zhao Kuai-le 1 , Hu Xi-chun 2 , Wu Xiang-hua 2 , Fu Xiao-long 1 , Fan Min 1 , Jiang Guo-liang 1

Download Presentation

Zhao Kuai-le 1 , Hu Xi-chun 2 , Wu Xiang-hua 2 , Fu Xiao-long 1 , Fan Min 1 , Jiang Guo-liang 1

An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -

Presentation Transcript


Zhao kuai le 1 hu xi chun 2 wu xiang hua 2 fu xiao long 1 fan min 1 jiang guo liang 1

A phase I dose escalation study of Nimotuzumabin combination with concurrent chemoradiation for patients with locally advanced squamous cell carcinoma of esophagus

(presentation number 1026)

Zhao Kuai-le1, Hu Xi-chun2, Wu Xiang-hua2, Fu Xiao-long1, Fan Min1, Jiang Guo-liang1

Fudan University Shanghai Cancer Center

Shanghai 20032, China


Zhao kuai le 1 hu xi chun 2 wu xiang hua 2 fu xiao long 1 fan min 1 jiang guo liang 1

Patient eligibility

(1) cytologically or histologically confirmed esophageal carcinoma; (2) age of 18–75; (3) locally advanced, stage II-IVa (AJCC, 2002); (4) performance status of ECOG 0–2; (5) no treatments prior to enrollment; (6) at least one measurable lesion on CT, MRI or esophageal barium exam; (6) normal functions of heart, lung, liver, kidney and bone marrow; (7) blood exams qualified for chemotherapy, which included hemoglobulin of ≥9 g/dl, neutrophil ≥1.5×109/L and platelet (PLT) ≥100×109/L, creatinine ≤1.5 UNL; and (8) informed consent signed

Study design

DDP: 25 mg/m2/d, d1-3, 5-FU: 1,800 mg/m2, continuous infusion in 72 h, every 4 weeks for 4 cycles; Irradiation: total dose of 61.2 Gy/34 fractions, 6.8 weeks; h-R3: weekly administration for 6 weeks, the dose escalation started with 100 mg, and followed by 200 mg and 400 mg. 3 patients will enrolled for each dose cohort.


Zhao kuai le 1 hu xi chun 2 wu xiang hua 2 fu xiao long 1 fan min 1 jiang guo liang 1

Results: Jul, 2009----Jun, 2010, 11 patients enrolled,h-R3 100mg/W=3cases, 200mg/W=4 cases, 400mg/W=4 cases, 2 patients withdrawed(200mg&400mg 1 cases, respectively)Median follow up 10.4 months(9.5-18 months). CR 22%, PR 56%, SD22%; 1 year OS 67%, LPFS 100% for 9 patients.


Zhao kuai le 1 hu xi chun 2 wu xiang hua 2 fu xiao long 1 fan min 1 jiang guo liang 1

Summary

1. h-R3 of 400 mg weekly with concurrent radiotherapy and PF regimen chemotherapy was safe and well-tolerated. Maximum tolerate dose (MTD) of h-R3 has not reached yet in this study.

2. The preliminary results of outcome were encouraging.


  • Login